GlassScriptPhysician profile
Edilberto Benitez
NPI 1104168673
$43,759.49
in general payments reported to CMS, 2019-2025
45 companies · $5,738 in 2025
The $5,738 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $9,963 · 2021: $706 · 2022: $1,837 · 2023: $1,504 · 2024: $2,177 · 2025: $5,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,193 · Travel and Lodging: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,193.42 |
| Travel and Lodging | $2,226.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15,385.77 | 2019-2020 | |
| Boston Scientific Corporation | $10,455.17 | 2019-2025 | General - Tachy, Watchman Flx |
| Abbott Laboratories | $5,068.92 | 2020-2025 | Amplatzer Talisman, Aveir |
| Medtronic, INC. | $4,968.50 | 2021-2025 | Affera Mapping System, Linq II, Pulseselect |
| Medical Device Business Services, INC. | $1,175.69 | 2019 | |
| Biosense Webster, INC. | $1,018.27 | 2021-2025 | Carto 3, Nuvision Ice Catheter, Octaray Mapping Catheter |
| Cvrx, INC. | $783.92 | 2022-2025 | Barostim Neo System |
| Abiomed | $782.66 | 2022-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $413.95 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $360.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $360.02 | 2021-2025 | Verquvo |
| Biotronik INC. | $341.19 | 2021-2022 | |
| Pfizer INC. | $339.37 | 2022-2025 | |
| Amgen INC. | $225.51 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.42 | 2019-2025 | Lifevest |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edilberto Benitez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.